#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	19	13862	16S	1529	1529	100.0	16S.l6.c30.ctg.1	2273	709.7	1	SNP	n	C1184T	0	.	.	1184	1184	C	1662	1662	C	877	C	877	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	23702	23S	2890	2890	99.9	23S.l6.c4.ctg.1	4114	717.7	0	.	n	.	0	T695C	SNP	695	695	T	1349	1349	C	854	C,T	852,2	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	23702	23S	2890	2890	99.9	23S.l6.c4.ctg.1	4114	717.7	0	.	n	.	0	G1337A	SNP	1337	1337	G	1991	1991	A	1003	A	1003	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	23702	23S	2890	2890	99.9	23S.l6.c4.ctg.1	4114	717.7	0	.	n	.	0	T1971C	SNP	1971	1971	T	2625	2625	C	818	C,A	817,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	23702	23S	2890	2890	99.9	23S.l6.c4.ctg.1	4114	717.7	1	SNP	n	A2045G	0	.	.	2045	2045	A	2699	2699	A	791	A,T,C	789,1,1	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	23702	23S	2890	2890	99.9	23S.l6.c4.ctg.1	4114	717.7	1	SNP	n	C2597T	0	.	.	2597	2597	C	3251	3251	C	810	C,T,A,G	805,3,1,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_V_01427c	folP.WHO_V_01427c	1	1	27	1890	folP	855	855	100.0	folP.l15.c4.ctg.1	2082	113.3	1	SNP	p	R229S	1	.	.	685	687	AGC	1238	1240	AGC	155;153;153	A,G;G;C	153,1;153;153	folP.WHO_V_01427c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	4546	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3997	141.7	1	SNP	p	S91F	1	.	.	271	273	TTC	907	909	TTC	180;181;182	T,C;T;C	179,1;181;182	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	4546	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3997	141.7	1	SNP	p	D95G	1	.	.	283	285	GGC	919	921	GGC	187;187;186	G,A;G,T,A;C	186,1;185,1,1;186	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	4546	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3997	141.7	1	SNP	p	G95N	0	.	.	283	285	GGC	919	921	GGC	187;187;186	G,A;G,T,A;C	186,1;185,1,1;186	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_G_01393	mtrR.WHO_G_01393	1	1	27	1908	mtrR	633	633	100.0	mtrR.l15.c4.ctg.1	1787	133.2	1	SNP	p	G45D	0	.	.	133	135	GGC	679	681	GGC	240;238;243	G,T;G;C	239,1;238;243	mtrR.WHO_G_01393:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	972	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c4.ctg.1	1581	76.7	0	.	n	.	0	A197.	DEL	197	197	A	884	884	A	183	A	183	.	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	4508	parC	2304	2304	100.0	parC.l6.c17.ctg.1	3471	161.4	1	SNP	p	D86N	0	.	.	256	258	GAC	810	812	GAC	207;205;207	G;A,C;C	207;204,1;207	parC.WHO_Y_00247c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	4508	parC	2304	2304	100.0	parC.l6.c17.ctg.1	3471	161.4	1	SNP	p	R87I	0	.	.	259	261	CGT	813	815	CGT	206;205;204	C,T;G;T,C	205,1;205;202,2	parC.WHO_Y_00247c:1:1:R87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	4508	parC	2304	2304	100.0	parC.l6.c17.ctg.1	3471	161.4	1	SNP	p	R87W	0	.	.	259	261	CGT	813	815	CGT	206;205;204	C,T;G;T,C	205,1;205;202,2	parC.WHO_Y_00247c:1:1:R87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	4508	parC	2304	2304	100.0	parC.l6.c17.ctg.1	3471	161.4	1	SNP	p	S87R	1	.	.	259	261	CGT	813	815	CGT	206;205;204	C,T;G;T,C	205,1;205;202,2	parC.WHO_Y_00247c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	4508	parC	2304	2304	100.0	parC.l6.c17.ctg.1	3471	161.4	1	SNP	p	S88P	0	.	.	262	264	TCC	816	818	TCC	208;210;208	T,G;C,T;C	207,1;209,1;208	parC.WHO_Y_00247c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	3830	parE	1986	1986	100.0	parE.l6.c30.ctg.1	3084	154.5	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1737	1739	GGC	242;240;240	G;G;C	242;240;240	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.5.002	penA.5.002	1	1	27	3636	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2856	158.4	1	SNP	p	A311V	0	.	.	931	933	GCA	1478	1480	GCA	205;209;207	G;C;A	205;209;207	penA.5.002:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	3636	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2856	158.4	1	SNP	p	I312M	0	.	.	934	936	ATC	1481	1483	ATC	205;205;204	A,T;T,A;C	204,1;204,1;204	penA.5.002:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	3636	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2856	158.4	1	SNP	p	V316T	0	.	.	946	948	GTG	1493	1495	GTG	205;203;203	G;T;G	205;203;203	penA.5.002:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	3636	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2856	158.4	1	SNP	p	V316P	0	.	.	946	948	GTG	1493	1495	GTG	205;203;203	G;T;G	205;203;203	penA.5.002:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	3636	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2856	158.4	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1997	1999	ACC	185;182;182	A;C;C	185;182;182	penA.5.002:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	3636	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2856	158.4	1	SNP	p	A502P	0	.	.	1504	1506	GCG	2051	2053	GCG	196;195;194	G,A;C,T,G;G,A	195,1;192,2,1;193,1	penA.5.002:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	3636	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2856	158.4	1	SNP	p	A502V	0	.	.	1504	1506	GCG	2051	2053	GCG	196;195;194	G,A;C,T,G;G,A	195,1;192,2,1;193,1	penA.5.002:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	3636	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2856	158.4	1	SNP	p	G543S	1	.	.	1627	1629	AGC	2174	2176	AGC	204;201;202	A;G,A;C	204;200,1;202	penA.5.002:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	3636	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2856	158.4	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2183	2185	GGC	209;209;209	G;G;C	209;209;209	penA.5.002:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	3636	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2856	158.4	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2201	2203	CCG	213;211;213	C,G;C,G;G	212,1;210,1;213	penA.5.002:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	4828	ponA	2397	2397	100.0	ponA.l15.c4.ctg.1	3483	172.5	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1764	1766	CCG	189;190;190	C;C;G	189;190;190	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2180	porA	1146	1146	99.91	porA.l6.c4.ctg.1	2306	117.7	0	.	p	.	0	M83fs	FSHIFT	247	247	A	856	856	C	136	C,A	135,1	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	512	280	porB1a	984	226	90.71	porB1a.l15.c30.ctg.1	372	24.1	0	.	p	.	0	V258L	NONSYN	772	774	GTA	14	16	TTA	28;33;35	T;T;A	28;33;35	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	512	280	porB1a	984	226	90.71	porB1a.l15.c30.ctg.1	372	24.1	0	.	p	.	0	Y273H	NONSYN	817	819	TAT	59	61	CAT	57;57;57	C;A;T	57;57;57	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	512	280	porB1a	984	226	90.71	porB1a.l15.c30.ctg.1	372	24.1	0	.	p	.	0	D274S	NONSYN	820	822	GAT	62	64	AGT	57;57;57	A;G;T	57;57;57	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	512	280	porB1a	984	226	90.71	porB1a.l15.c30.ctg.1	372	24.1	0	.	p	.	0	N277Y	NONSYN	829	831	AAC	71	73	TAC	57;57;57	T;A,C;C	57;56,1;57	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	512	280	porB1a	984	226	90.71	porB1a.l15.c30.ctg.1	372	24.1	0	.	p	.	0	R307A	NONSYN	919	921	AGA	161	163	GCA	1;1;1	G;C;A	1;1;1	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	512	280	porB1a	984	226	90.71	porB1a.l15.c30.ctg.1	372	24.1	0	.	p	.	0	T311A	NONSYN	931	933	ACA	173	175	GCA	1;1;1	G;C;A	1;1;1	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	512	280	porB1a	984	226	90.71	porB1a.l15.c30.ctg.1	372	24.1	0	.	p	.	0	E312D	NONSYN	934	936	GAA	176	178	GAC	1;1;1	G;A;C	1;1;1	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	512	280	porB1a	984	226	90.71	porB1a.l15.c30.ctg.1	372	24.1	0	.	p	.	0	F314I	NONSYN	940	942	TTC	182	184	ATC	1;1;1	A;T;C	1;1;1	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	512	280	porB1a	984	226	90.71	porB1a.l15.c30.ctg.1	372	24.1	0	.	p	.	0	V318A	NONSYN	952	954	GTC	194	196	GCC	3;3;3	G;C;C	3;3;3	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	512	280	porB1a	984	226	90.71	porB1a.l15.c30.ctg.1	372	24.1	0	.	p	.	0	G319S	NONSYN	955	957	GGC	197	199	AGC	3;3;3	A;G;C	3;3;3	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	512	280	porB1a	984	226	90.71	porB1a.l15.c30.ctg.1	372	24.1	0	.	p	.	0	G320A	NONSYN	958	960	GGT	200	202	GCC	3;3;3	G;C;C	3;3;3	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	512	280	porB1a	984	226	90.71	porB1a.l15.c30.ctg.1	372	24.1	0	.	p	.	0	G322V	NONSYN	964	966	GGT	206	208	GTT	3;3;3	G;T;T	3;3;3	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	512	280	porB1a	984	100	94.0	porB1a.l15.c30.ctg.4	182	50.8	0	.	p	.	0	M18T	NONSYN	52	54	ATG	133	135	ACG	56;55;52	A,C;C,T;G	55,1;54,1;52	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	512	280	porB1a	984	100	94.0	porB1a.l15.c30.ctg.4	182	50.8	0	.	p	.	0	E32Q	NONSYN	94	96	GAA	175	177	CAA	11;10;9	C;A;A	11;10;9	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2684	porB1b	1047	1047	99.33	porB1b.l15.c17.ctg.1	1857	178.2	0	.	p	.	0	N38E	NONSYN	112	114	AAT	581	583	GAA	243;242;243	G,A;A,G;A,C	242,1;240,2;242,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2684	porB1b	1047	1047	99.33	porB1b.l15.c17.ctg.1	1857	178.2	0	.	p	.	0	N134D	NONSYN	400	402	AAT	869	871	GAT	222;219;221	G,C;A;T	221,1;219;221	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2684	porB1b	1047	1047	99.33	porB1b.l15.c17.ctg.1	1857	178.2	0	.	p	.	0	P175S	NONSYN	523	525	CCA	992	994	TCA	247;250;250	T,G;C;A	246,1;250;250	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2684	porB1b	1047	1047	99.33	porB1b.l15.c17.ctg.1	1857	178.2	0	.	p	.	0	A218V	NONSYN	652	654	GCC	1121	1123	GTC	217;218;217	G;T;C	217;218;217	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2684	porB1b	1047	1047	99.33	porB1b.l15.c17.ctg.1	1857	178.2	0	.	p	.	0	E328A	NONSYN	982	984	GAA	1451	1453	GCA	220;221;223	G;C;A	220;221;223	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2684	porB1b	1047	1047	99.33	porB1b.l15.c17.ctg.1	1857	178.2	1	SNP	p	G120K	1	.	.	358	360	AAG	827	829	AAG	228;231;232	A;A;G,C	227;231;231,1	porB1b.WHO_V_02265c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2684	porB1b	1047	1047	99.33	porB1b.l15.c17.ctg.1	1857	178.2	1	SNP	p	A121D	1	.	.	361	363	GAC	830	832	GAC	231;233;233	G;A;C	231;233;233	porB1b.WHO_V_02265c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2684	porB1b	1047	1047	99.33	porB1b.l15.c17.ctg.1	1857	178.2	1	SNP	p	D121N	0	.	.	361	363	GAC	830	832	GAC	231;233;233	G;A;C	231;233;233	porB1b.WHO_V_02265c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	8848	rpoB	4179	4179	99.98	rpoB.l6.c30.ctg.1	5554	198.8	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1242	rpsJ	312	312	100.0	rpsJ.l6.c4.ctg.1	1696	91.5	1	SNP	p	V57M	1	.	.	169	171	ATG	823	825	ATG	209;208;207	A;T;G,A	209;208;205,1	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
